TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Japanese male or female~Exclusion Criteria:~* Has a history of invasive pneumococcal disease (IPD)~* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid containing vaccine~* Has a known or suspected impairment of immunological function~* Has a history of congenital or acquired immunodeficiency~* Has or his/her mother has a documented human immunodeficiency virus (HIV) infection~* Has or his/her mother has a documented hepatitis B surface antigen-positive test~* Has known or history of functional or anatomic asplenia~* Has a history of autoimmune disease~* Has a known neurologic or cognitive behavioral disorder~* Has received a dose of any pneumococcal vaccine prior to study entry~* Has received a blood transfusion or blood products, including immunoglobulins

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.
- Pneumococcal 13-valent Conjugate Vaccine (PCV13) (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of \>20~* Patients will need to sign an informed consent before any visit procedures can be performed, including procedures for the optional genetic research and biomarker studies.~* Patients must be 18 years or older and will be asked to stop taking any current cholesterol-lowering medications. Dietary counselling will be provided which will include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will be asked to follow~Exclusion Criteria:~* Use of lipid lowering drugs and other prohibited concomitant medications. History of statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history of hypersensitivity to any components of ezetimibe.~* Patients considered to be unstable by their physician after the following events:~a myocardial infarction, recent episode of unstable angina, myocardial revascularisation \[percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure\] or a transient ischaemic attack (TIA) or stroke and patients awaiting a planned myocardial revascularisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eye Muscle Needle Electromyogram (EMu) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~i. Adults undergoing planned, routine EMG needle guided BTX injection into either lateral or medial rectus muscle for the treatment of strabismus.~ii. Patients being treated by Mr Yagan.~Exclusion Criteria:~- Patients with Chronic progressive external ophthalmoplegia (CPEO) are excluded; a highly attenuated EMG signal is expected.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sym004 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Part A:~1. Patients with refractory or recurrent advanced late stage solid tumors without available therapeutic options .~Part B, C, D, E and F:~1. Patients with refractory or recurrent advanced mCRC and wild-type KRAS who have progressed on epidermal growth factor receptor (EGFR) Ab treatment.~2. Patients wit confirmed response while on treatment anti-EGFR Ab treatment.~3. Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.~4. Patients must be willing to have a biopsy performed from a tumor lesion at screening and at Visit 6.~Part A, B, C, D, E and F:~1. Histologically or cytologically confirmed diagnosis of cancer~2. Failure and/or intolerance to standard chemotherapy~3. Life expectancy of at least 3 months~4. Eastern Cooperative Oncology Group (ECOG) performance status ≤2~Exclusion Criteria:~1. Patients with clinically symptomatic brain metastases.~2. Received the following treatments prior to Visit 2:~   * Cytotoxic or cytostatic anti-cancer chemotherapy within 4 weeks~  * Total resection or irradiation of the target lesion~  * Antibody therapy within 4 weeks and vaccines within 12 weeks~  * Tyrosin kinase inhibitors within 4 weeks~  * Any investigational agent within 4 weeks~3. Diarrhea CTCAE \>1~4. Skin rash CTCAE \>1~5. Abnormal organ or bone marrow function.~6. Use of immunosuppressive agents for the past 4 weeks prior to trial start, including systemic corticosteroids used at doses above 20mg/day of prednisolone or equivalent.~7. History of other malignancy within 5 years prior to trial start, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix (not in Part A).~8. Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the investigator.~9. Known HIV positive~10. Known active hepatitis B or C~11. Patients with known uncontrolled allergic conditions or allergy to the study drug and/or their components.~12. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities and controlled and well treated chronic atrial fibrillation.~13. Significant concurrent, uncontrolled medical condition evaluated by the investigator to interfere with effect of the trial drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sym004 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline for the Treatment of Early-Phase Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age between 18-35 years;~2. current DSM-IV diagnosis of schizophrenia confirmed by the Structured Clinical Interview for DSM-IV (SCID) conducted by a trained psychiatrist.~3. being at an early phase of the disorder (i.e., within five years of their first exposure to neuroleptic treatment;18)~4. did not receive antipsychotic treatment for six months preceding current symptom exacerbation;~5. baseline total score of more than 60 on the Positive and Negative Syndrome Scale (PANSS).~6. Initiation of treatment with atypical antipsychotic medication equal or less than 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/day chlorpromazine equivalent doses);~7. able to comprehend the procedure and aims of the study.~Exclusion Criteria:~1. acute, unstable, significant or untreated medical illness beside schizophrenia;~2. pregnant or breast-feeding females;~3. A DSM-IV diagnosis of substance abuse or dependency;~4. Known contraindication to minocycline treatment.~5. Treatment with minocycline or Beta-lactam antibiotics in the preceding half year before study entry.~6. Under compulsory hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Minocycline treatment
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological confirmation of non-small cell lung cancer~2. Patients who have been treated in the past with stereotactic radiosurgery, stereotactic radiotherapy, GliaSite or surgical resection will be allowed to enroll in this study~3. A diagnostic contrast-enhanced MRI or CT scan must be performed, demonstrating brain metastases~4. Age 18-70~5. Patients must have KPS \>/= 70~6. Patients cannot be treated on any other treatment related protocols within 30 days prior to study entry or during participation in the study~7. No uncontrolled or symptomatic major medical illnesses or psychiatric impairments, such as Alzheimer's or schizophrenia~8. Screening Clinical Laboratory Values: ANC \>1500/ul, Platelets \>80,000/ul, baseline AST and/or ALT within normal limits (within 30 days of starting protocol treatment)~9. All women of childbearing potential (A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months \[i.e., who has had menses at any time in the preceding 24 consecutive months\]) and male participants must practice effective contraception (abstinence, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.~10. Continued from #10: All women of child-bearing potential must have a negative serum pregnancy test and practice birth control while on study.~11. Patients must provide verbal and written informed consent to participate in the study.~Exclusion Criteria:~1. Prior cranial radiation therapy, other than stereotactic radiosurgery, Stereotactic Radiotherapy or GliaSite.~2. Patients with known Acquired Immune Deficiency (AIDS), as regimens with tyrosine kinase inhibitors may pose a safety risk related to excess toxicity or interference with anti-viral effectiveness~3. Women who are pregnant or lactating, due to possible adverse effects on the developing fetus or infant due to study drug~4. Patients with active connective tissue disorders, such as lupus or scleroderma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tarceva + RT (Type: EXPERIMENTAL): Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects between the ages of 30 and 65 (inclusive) at the time of the informed consent process~* have an average clinic BP in the high normal range of \< 139/85-89 mmHg or 130-139/\< 89 mm Hg (high normal BP range) (mean systolic and/or diastolic pressure based on 3 consecutive measurements) derived from the average of clinic visits 1,2 and 3.~Exclusion Criteria:~* Have proteinuria \>1 + (by dipstick method)~* have a stroke, myocardial infarction (MI), transient ischemic attack (TIA), the presence of any clinically significant evidence of atherosclerosis or hypertensive target organ involvement or any significant medical condition that may compromise participation in this study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed of Asherman Syndrome and absence of pregnancy after treatment~* Endometrial atrophy (\<6mm) with Implantation Failure~* Age 20-45 years-old~* Normal liver, heart and kidney function~* Presence of menstrual bleeding with Natural Cycle or HRT~* Absence of psychiatric pathology and ability to accomplish the treatment~* β-hCG negative~* Absence of SDT~Exclusion Criteria:~* Absence of peripheral vein access~* Lack of accomplish inclusion criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 17 years of age or older~* Stable cancer-related pain.~* Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain for at least 14 days prior to screening.~* Experiencing 1-4 episodes of breakthrough pain per day.~* Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.~Exclusion Criteria:~* Are pregnant or lactating.~* Have uncontrolled or rapidly escalating pain.~* Have moderate to severe ulcerative mucositis.~* Have a cardiopulmonary disease that would increase the risk of administering potent opioids.~* Have neurologic or psychologic disease that would compromise data collection~* Have any clinically significant condition that would, in the investigator's opinion, preclude study participation.~* Are currently taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.~* Have received strontium 89 therapy within 60 days prior to entering the study.~* Have received anti-neoplastic therapy within 2 weeks of study entry that, in the investigator's opinion, will influence assessment of breakthrough pain~* Have received any investigational drug (non-approved) within 30 days prior to the first dose of study medication, or are scheduled to receive an investigational drug other than EN3267 during the course of the study.~* Have hypersensitivities, allergies, or contraindications to fentanyl.~* Have a significant prior history of substance abuse or alcohol abuse.~* May have difficulty complying with the protocol, as assessed by the investigator.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Dental students of Dental school of Melaka-Manipal Medical College~Exclusion Criteria:~* Participants who had systemic diseases~* Gingivitis or periodontitis~* Use of antibiotics in the past 3 months,~* Pregnancy,~* Smoking~* Orthodontic appliances.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 28 Years
- Healthy Volunteers: t

Study Arms:
- Brushing First and Flossing Later (BF) (Type: EXPERIMENTAL): The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
- Flossing First and Brushing Later (FB) (Type: EXPERIMENTAL): The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 - 75 years~* Essential hypertension not well controlled by current low dose (80 mg) valsartan monotherapy for at least 4 weeks. Patients on prior treatment with monotherapy diuretic, ACE-I or beta blocker or an ARB other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible, provided the hypertension is still not well controlled.~* Office systolic blood pressure (sitting) \>140 mmHg (sitting for \>/= 5 min., no cigarettes and/or coffee/tea for \>/=30 min. before BP measurement).~* BMI \<33 kg/m2~Exclusion Criteria:~* Participation in any clinical investigational drug study within the previous 12 weeks~* Concomitant treatments with:~  1. Any anti-hypertensive treatment other than Valsartan 80 mg~ 2. Cytochrome P450-3A4 inhibitors or inducers~ 3. Potassium-sparing diuretics~* Severe hypertension (DBP \>/= 110 mm Hg and/or SBP \>/= 180 mm Hg) and/or evidence of secondary forms of hypertension~* Any of the following cardiovascular diseases:~* History of cardiovascular shock~* Myocardial infarction or unstable angina within the previous 6 months~* Severe cardiac valve disease~* Past or present severe rhythm or conduction disorder.~* Cerebrovascular ischemic event and/or history of intracerebral hemorrhage or subarachnoid hemorrhage (SAH) within the previous 12 months~* Type 1 or 2 diabetes mellitus~* Proteinuria~* Uncorrected hypokalemia or hyperkalemia, sodium depletion and/or hypovolemia~* Gastrointestinal disease resulting in the potential for malabsorption and/or severe gastro-intestinal tract narrowing; kock pouch (ileostomy after proctocolectomy)~* Cholestasis or biliary obstruction~* Liver disease or aspartate aminotransferase (AST) / alanine aminotransferase (ALT) levels \>3 x upper limits of normal (ULN)~* Renal failure, creatinine level \>2.0 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete